167 related articles for article (PubMed ID: 25593612)
1. Two Qatari siblings with cystic fibrosis and apparent mineralocorticoid excess.
Zahraldin K; Janahi IA; Ben-Omran T; Alsulaiman R; Hamad B; Imam A
Ann Thorac Med; 2015; 10(1):69-72. PubMed ID: 25593612
[TBL] [Abstract][Full Text] [Related]
2. A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension.
Odermatt A; Dick B; Arnold P; Zaehner T; Plueschke V; Deregibus MN; Repetto H; Frey BM; Frey FJ; Ferrari P
J Clin Endocrinol Metab; 2001 Mar; 86(3):1247-52. PubMed ID: 11238516
[TBL] [Abstract][Full Text] [Related]
3. Apparent mineralocorticoid excess syndrome: report of one family with three affected children.
Al-Harbi T; Al-Shaikh A
J Pediatr Endocrinol Metab; 2012; 25(11-12):1083-8. PubMed ID: 23329753
[TBL] [Abstract][Full Text] [Related]
4. [From gene to disease; 'apparent mineralocorticoid excess' syndrome, a syndrome with an apparent excess of mineral corticoids].
Levtchenko EN; Deinum J; Knoers NV; Hermus AR; Monnens LA; Lenders JW
Ned Tijdschr Geneeskd; 2007 Mar; 151(12):692-4. PubMed ID: 17447595
[TBL] [Abstract][Full Text] [Related]
5. Apparent mineralocorticoid excess caused by novel compound heterozygous mutations in HSD11B2 and characterized by early-onset hypertension and hypokalemia.
Fan P; Lu YT; Yang KQ; Zhang D; Liu XY; Tian T; Luo F; Wang LP; Ma WJ; Liu YX; Zhang HM; Song L; Cai J; Lou Y; Zhou XL
Endocrine; 2020 Dec; 70(3):607-615. PubMed ID: 32816205
[TBL] [Abstract][Full Text] [Related]
6. Human hypertension caused by mutations in the 11 beta-hydroxysteroid dehydrogenase gene: a molecular analysis of apparent mineralocorticoid excess.
Whorwood CB; Stewart PM
J Hypertens Suppl; 1996 Dec; 14(5):S19-24. PubMed ID: 9120678
[TBL] [Abstract][Full Text] [Related]
7. Apparent mineralocorticoid excess and the long term treatment of genetic hypertension.
Razzaghy-Azar M; Yau M; Khattab A; New MI
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt A):145-150. PubMed ID: 26892095
[TBL] [Abstract][Full Text] [Related]
8. Apparent mineralocorticoid excess: report of six new cases and extensive personal experience.
Morineau G; Sulmont V; Salomon R; Fiquet-Kempf B; Jeunemaître X; Nicod J; Ferrari P
J Am Soc Nephrol; 2006 Nov; 17(11):3176-84. PubMed ID: 17035606
[TBL] [Abstract][Full Text] [Related]
9. Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation.
Ferrari P; Krozowski Z
Kidney Int; 2000 Apr; 57(4):1374-81. PubMed ID: 10760070
[TBL] [Abstract][Full Text] [Related]
10. Apparent mineralocorticoid excess syndrome: an overview.
Palermo M; Quinkler M; Stewart PM
Arq Bras Endocrinol Metabol; 2004 Oct; 48(5):687-96. PubMed ID: 15761540
[TBL] [Abstract][Full Text] [Related]
11. The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension.
Ferrari P; Lovati E; Frey FJ
J Hypertens; 2000 Mar; 18(3):241-8. PubMed ID: 10726708
[TBL] [Abstract][Full Text] [Related]
12. Apparent Mineralocorticoid Excess in the Pediatric Population: Report of a Novel Pathogenic Variant of the 11β-HSD2 Gene and Systematic Review of the Literature.
Adamidis A; Cantas-Orsdemir S; Tsirka A; Abbott MA; Visintainer P; Tonyushkina K
Pediatr Endocrinol Rev; 2019 Mar; 16(3):335-358. PubMed ID: 30888125
[TBL] [Abstract][Full Text] [Related]
13. Clinical, Biochemical, and Genetic Characteristics of "Nonclassic" Apparent Mineralocorticoid Excess Syndrome.
Tapia-Castillo A; Baudrand R; Vaidya A; Campino C; Allende F; Valdivia C; Vecchiola A; Lagos CF; Fuentes CA; Solari S; Martínez-Aguayo A; García H; Carvajal CA; Fardella CE
J Clin Endocrinol Metab; 2019 Feb; 104(2):595-603. PubMed ID: 30239803
[TBL] [Abstract][Full Text] [Related]
14. 11beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
White PC
Am J Med Sci; 2001 Dec; 322(6):308-15. PubMed ID: 11780688
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess.
Li A; Tedde R; Krozowski ZS; Pala A; Li KX; Shackleton CH; Mantero F; Palermo M; Stewart PM
Am J Hum Genet; 1998 Aug; 63(2):370-9. PubMed ID: 9683587
[TBL] [Abstract][Full Text] [Related]
16. Congenital deficiency of 11beta-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): diagnostic value of urinary free cortisol and cortisone.
Palermo M; Delitala G; Mantero F; Stewart PM; Shackleton CH
J Endocrinol Invest; 2001 Jan; 24(1):17-23. PubMed ID: 11227727
[TBL] [Abstract][Full Text] [Related]
17. Apparent mineralocorticoid excess (AME) syndrome.
Parvez Y; Sayed OE
Indian Pediatr; 2013 Apr; 50(4):416-8. PubMed ID: 23665601
[TBL] [Abstract][Full Text] [Related]
18. The role of 11β-hydroxysteroid dehydrogenase type 2 in human hypertension.
Ferrari P
Biochim Biophys Acta; 2010 Dec; 1802(12):1178-87. PubMed ID: 19909806
[TBL] [Abstract][Full Text] [Related]
19. Genetic, biochemical, and clinical studies of patients with A328V or R213C mutations in 11betaHSD2 causing apparent mineralocorticoid excess.
Morineau G; Marc JM; Boudi A; Galons H; Gourmelen M; Corvol P; Pascoe L; Fiet J
Hypertension; 1999 Sep; 34(3):435-41. PubMed ID: 10489390
[TBL] [Abstract][Full Text] [Related]
20. Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 deficiency.
Yau M; Haider S; Khattab A; Ling C; Mathew M; Zaidi S; Bloch M; Patel M; Ewert S; Abdullah W; Toygar A; Mudryi V; Al Badi M; Alzubdi M; Wilson RC; Al Azkawi HS; Ozdemir HN; Abu-Amer W; Hertecant J; Razzaghy-Azar M; Funder JW; Al Senani A; Sun L; Kim SM; Yuen T; Zaidi M; New MI
Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11248-E11256. PubMed ID: 29229831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
